GeNeuro is a series a startup. 1 investor tracked.
GeNeuro is a startup based in Switzerland. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
GeNeuro is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and autoimmune diseases by targeting human endogenous retroviruses (HERVs). Its lead candidate, temelimab, is a monoclonal antibody designed to neutralize pathogenic proteins associated with conditions like multiple sclerosis, amyotrophic lateral sclerosis, and post-COVID neuropsychiatric syndromes.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.